F1000Research | |
Circulating tumor cells: silent predictors of metastasis [version 1; referees: 2 approved] | |
Wafik S. El-Deiry1  Elizabeth Matthew1  R. Katherine Alpaugh1  David T. Dicker1  LanLan Zhou1  | |
[1] Fox Chase Cancer Center, Philadelphia, PA, USA; | |
关键词: Breast Diseases: Benign & Malignant; Cancer Therapeutics; Cell Growth & Division; Gastrointestinal Cancers; Genitourinary Cancers; Genomics; Lung Cancer; Medical Genetics; | |
DOI : 10.12688/f1000research.11313.1 | |
来源: DOAJ |
【 摘 要 】
Circulating tumor cells (CTCs) were added to the arsenal of clinical testing in 2004 for three cancer types: metastatic breast, prostate, and colorectal cancer. CTCs were found to be an independent prognostic indicator of survival for these three diseases. Multiple enrichment/isolation strategies have been developed and numerous assay applications have been performed using both single and pooled captured/enriched CTCs. We have reviewed the isolation techniques and touched on many analyses. The true utility of a CTC is that it acts as a “silent” predictor of metastatic disease. The mere presence of a single CTC is an indication that disease has spread from the primary site. Comments and suggestions have been set forth for CTCs and cell-free DNA to be used as a screening panel for the early detection of disease recurrence and metastatic spread, providing the opportunity for early intervention with curative intent to treat metastatic disease.
【 授权许可】
Unknown